Figure 5.
Therapy with the B16/DC.GM fusion vaccine prolongs the survival time of tumour-bearing mice. B6 mice were given an intravenous (i.v.) injection of 2×105 B16 tumour cells to establish tumours. Three days after tumour inoculation, mice were divided into five groups and were treated by three vaccinations, at weekly intervals, with 2×106 irradiated B16, B16.GM, DC.GM, B16/DC.GM or B16/DC cells. The survival times of each group of mice were monitored. The data presented were pooled from two separate experiments.